Tom Andries

19 Flips | 1 Magazine | 48 Likes | 1 Following | 1 Follower | @TomAndries2015 | Keep up with Tom Andries on Flipboard, a place to see the stories, photos, and updates that matter to you. Flipboard creates a personalized magazine full of everything, from world news to life’s great moments. Download Flipboard for free and search for “Tom Andries”

Cellceutix keen to move psoriasis treatment onto phase III

Cellceutix Corporation (OTC:CTIX) wants to move its psoriasis treatment Prurisol into phase III trials as quickly as possible, chief executive Leo …

Biotechnology

Cellceutix Phase 2 Trial of Prurisol for Mild to Moderate Psoriasis Meets Primary Endpoint

BEVERLY, MA--(Marketwired - May 24, 2016) -<p>Clinical efficacy demonstrated in the highest dose (200mg) comparator arm<br>• Compound shown to be safe and …

Now Is The Time To Keep An Eye On CTIX...

Shares of Cellceutix Corp. (CTIX.OB) have gained over 24% year-to-date, and the impending results from the company's phase II trial of Prurisol for …

Biotechnology

Cellceutix Corporation Welcomes Dr. Stephen T. Sonis to Its Scientific Advisory Board

BEVERLY, MA--(Marketwired - March 08, 2016) - Cellceutix Corporation (CTIX) (the "Company"), a clinical stage biopharmaceutical company developing …

Assay Results from Cellceutix Phase 1 Clinical Trial of Kevetrin for Cancer Show Increased p21 Expression in 67.5% of Evaluable Patients

<b>Assay Results from Cellceutix Phase 1 Clinical Trial of Kevetrin for Cancer Show Increased p21 Expression in 67.5% of Evaluable Patients</b> <br>BEVERLY, …

Biotechnology

A Small-Cap Biotech with Big Ideas for Acute Infections and Cancers: Cellceutixs Leo Ehrlich and Dr. Daniel Jorgensen

<b>The Life Sciences Report</b>: Let's start with brilacidin. In August 2014, Cellceutix Corp. (CTIX:OTCMKTS) completed a 215-patient, Phase 2b study …

Biotechnology

FDA Grants Fast Track Designation to Cellceutix's Brilacidin-OM for Oral Mucositis

BEVERLY, MA--(Marketwired - November 25, 2015) - Cellceutix Corporation (CTIX) (the "Company"), a clinical stage biopharmaceutical company developing …

Cellceutix Retains Former Durata Executive Ronald Trust as Regulatory Affairs Consultant

BEVERLY, MA--(Marketwired - November 30, 2015) - Cellceutix Corporation (CTIX) (the "Company"), a clinical stage biopharmaceutical company developing …

Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of Retinoblastoma

BEVERLY, MA--(Marketwired - December 01, 2015) - Cellceutix Corporation (CTIX) (the "Company"), a clinical stage biopharmaceutical company developing …

Cellceutix Files Form 10-Q for Quarter Ended September 30, 2015

BEVERLY, MA--(Marketwired - November 10, 2015) - Cellceutix Corporation (CTIX) (the "Company"), a clinical stage biopharmaceutical company developing …

Cellceutix Provides Brilacidin Update; New Class of Antibiotics to Enter Phase 3

BEVERLY, MA--(Marketwired - October 30, 2015) - Cellceutix Corporation (CTIX) (the "Company"), a clinical stage biopharmaceutical company developing …

Cellceutix to Request Meeting With FDA for Phase 2 Ovarian Cancer Study; Company's First-in-Human Study Defines the Pharmacokinetic Profile of Kevetrin

BEVERLY, MA--(Marketwired - October 26, 2015) - Cellceutix Corporation (CTIX) (the "Company"), a clinical stage biopharmaceutical company developing …